Warfarin anticoagulation and outcomes in patients with atrial fibrillation: A systematic review and metaanalysis

Chest

Volumn 126, Issue 6, 2004, Pages 1938-1945

  Reynolds, Matthew W ^a,c   Fahrbach, Kyle ^a   Hauch, Ole ^b   Wygant, Gail ^b   Estok, Rhonda ^a   Cella, Catherine ^a   Nalysnyk, Luba ^a  

^a MetaWorks Inc   (United States)

^b ASTRAZENECA   (United Kingdom)

^c 10 President's Landing ^*  (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Warfarin

Indexed keywords

WARFARIN;

ANTICOAGULATION; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL STANDARD UNIT; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 10444278105     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.6.1938     Document Type: Article

References (48)

1. Akhtar W, Reeves WC, Movahed A. Indications for anticoagulation in atrial fibrillation. Am Fam Physician 1998; 58:130-135
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22:983-988
3. Singer D. Anticoagulation to prevent stroke in atrial fibrillation and its implications for managed care. Am J Cardiol 1998; 81:35C-40C
4. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323:150:5-1511
5. Petersen P, Godtfredsen J, Boysen G, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989; 1:175-179
6. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84:527-529
7. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18:349-355
8. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327:1406-1412
9. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1256-1262
10. Albers G, Dalen J, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation: Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001; 119:1948-2068
11. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997; 126:376-380
12. Mulrow CD, Oxman AD, eds. Cochrane collaboration handbook. The Cochrane Library. The Cochrane Collaboration; Issue 1. Oxford, UK: Update Software, 1997
13. Fleiss JL. Statistical methods for rates and proportions, 2nd ed. New York, NY: John Wiley & Sons, 1981
14. Albers GW, Bittar N, Young L, et al. Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals. Neurology 1997; 48:1598-1604
15. Ang SY, Peterson GM, Friesen WT, et al. Review of antithrombotic drug usage in atrial fibrillation. J Clin Pharm Ther 1998; 23:97-106
16. Blackshear JL, Zabalgoitia M, Pennock G, et al. Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. Am J Cardiol 1999; 83:453-455,A9
17. Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997; 28:2382-2389
18. Cohen N, Almoznino-Sarafian D, Alon I, et al. Adequacy of anticoagulation in patients with atrial fibrillation: effect of various parameters. Clin Cardiol 2001; 24:380-384
19. Cowburn P, Cleland JG. SPAF-III results. Eur Heart J 1996; 17:1129
20. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333:5-10
21. Ezekowitz MD, James KE, Nazarian SM, et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Circulation 1995; 92:2178-2182
22. Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Arch Intern Med 1999; 159:1322-1328
23. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998; 158:1513-1521
24. Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999; 319:958-964
25. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335:540-546
26. Kalra L, Yu G, Perez I, et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000; 320:1236-1239
27. Kimura M, Wasaki Y, Ogawa H, et al. Effect of low-intensity warfarin therapy on left atrial thrombus resolution in patients with nonvalvular atrial fibrillation: a transesophageal echocardiographic study. Jpn Circ J 2001; 65:271-274
28. Koefoed BG, Feddersen C, Gullov AL, et al. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation. Thromb Haemost 1997; 77:845-848
29. Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997; 28:1015-1021
30. Nozawa T, Asanoi H, Inoue H. Instability of anticoagulation intensity contributes to occurrence of ischemic stroke in patients with non-rheumatic atrial fibrillation. Jpn Circ J 2001; 65:404-408
31. Pengo V, Legnani C, Noventa F, et al. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding: a multicenter inception cohort study. Thromb Haemost 2001; 85:418-422
32. Pengo V, Zasso A, Barbero F, et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol 1998; 82:433-437
33. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156:409-416
34. The Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633-638
35. The Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343:687-691
36. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998; 128:639-647
37. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000; 31:817-821
38. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40:1183-1188
39. Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119:194S-206S
40. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001; 322:321-326
41. Van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288:2441-2448
42. Go AS, Hylek EM, Change Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice. JAMA 2003; 290:268.5-2692
43. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019-1026
44. Matchar DB, Samsa GP, Cohen SJ, et al. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med 2002; 113:42-51
45. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158:1641-1647
46. Samsa GP, Matchar DB, Phillips DL, et al. Which approach to anticoagulation management is best?: Illustration of an interactive mathematical model to support informed decision making. J Thromb Thrombol 2002; 14:103-111
47. Lafata JE, Martin SA, Kaatz S, et al. The cost-effectiveness of different management strategies for patients on chronic-warfarin therapy. J Gen Intern Med 2000; 15:31-37
48. O'Donnell M, Weitz JI. Novel antithrombotic therapies for the prevention of stroke in patients with atrial fibrillation. Am J Manag Care 2004; 10:S72-S82